Amoah Ransford, Danquah John, Mante Priscilla Kolibea
Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Heliyon. 2024 Jul 8;10(14):e34296. doi: 10.1016/j.heliyon.2024.e34296. eCollection 2024 Jul 30.
Demyelinating diseases are commonly associated with epileptic seizures and have limited management options. Hence, the need to investigate potential options for management of such seizures. extract (AE) was investigated for effect in chronic demyelinating seizures. Cuprizone treatment induced short but frequent spike discharges in mice. extract (300 mg/kg) treatment abolished epileptiform discharges. Cuprizone administration caused severe demyelination in the corpus callosum. After the demyelination phase, myelin content decreased to 22.86 ± 1.92 % in the cuprizone-only group. However, there was an increase to 52.14 ± 3.91 % in cuprizone-only group and 62.00 ± 2.78 % in the extract group respectively, after a 4-week cuprizone cessation period. Treatment with AE and LEV visibly altered myelin growth. extract treatment produced significant (P < 0.001, F (3, 16) = 698.4) increase in locomotor activity similar to LEV (P < 0.001,F (2, 12) = 678.7) and DZP (P < 0.001, F (2, 12) = 620.4) and improved beam traversal time (18.71 ± 2.244 s; 95 % CI: 13.22-24.20) while causing significantly (P < 0.05, F (2, 15) = 6.667) fewer stepping errors. extract inhibits seizures induced by chronic demyelination and has beneficial effects on motor coordination.
脱髓鞘疾病通常与癫痫发作相关，且治疗选择有限。因此，有必要研究针对此类癫痫发作的潜在治疗方案。研究了提取物（AE）对慢性脱髓鞘性癫痫发作的影响。用铜螯合剂治疗可在小鼠中诱发短暂但频繁的棘波放电。提取物（300mg/kg）治疗可消除癫痫样放电。给予铜螯合剂会导致胼胝体严重脱髓鞘。在脱髓鞘阶段后，仅使用铜螯合剂的组中髓磷脂含量降至22.86±1.92%。然而，在停止使用铜螯合剂4周后，仅使用铜螯合剂的组中髓磷脂含量分别增加至52.14±3.91%，提取物组中增加至62.00±2.78%。用AE和左乙拉西坦治疗明显改变了髓磷脂的生长。提取物治疗使运动活动显著增加（P<0.001，F(3,16)=698.4），类似于左乙拉西坦（P<0.001，F(2,12)=678.7）和地西泮（P<0.001，F(2,12)=620.4），并改善了横梁穿越时间（18.71±2.244秒；95%置信区间：13.22 - 24.20），同时显著减少了步幅错误（P<0.05，F(2,15)=6.667）。提取物可抑制慢性脱髓鞘诱发的癫痫发作，并对运动协调有有益作用。
